The gene expression signatures of melanoma progression

Christopher M. Haqq(Northern California Melanoma Center), Mehdi Nosrati(Northern California Melanoma Center), Daniel Sudilovsky(Northern California Melanoma Center), Julia Crothers(Northern California Melanoma Center), Daniel Khodabakhsh(Northern California Melanoma Center), Brian Pulliam(Northern California Melanoma Center), Scot Federman(Northern California Melanoma Center), James R. Miller(Northern California Melanoma Center), Robert E. Allen(Northern California Melanoma Center), Mark I. Singer(Northern California Melanoma Center), Stanley P. L. Leong(Northern California Melanoma Center), Britt‐Marie Ljung(Northern California Melanoma Center), Richard W. Sagebiel(Northern California Melanoma Center), Mohammed Kashani–Sabet(Northern California Melanoma Center)
Proceedings of the National Academy of Sciences
April 15, 2005
Cited by 433Open Access
Full Text

Abstract

Because of the paucity of available tissue, little information has previously been available regarding the gene expression profiles of primary melanomas. To understand the molecular basis of melanoma progression, we compared the gene expression profiles of a series of nevi, primary melanomas, and melanoma metastases. We found that metastatic melanomas exhibit two dichotomous patterns of gene expression, which unexpectedly reflect gene expression differences already apparent in comparing laser-capture microdissected radial and vertical phases of a large primary melanoma. Unsupervised hierarchical clustering accurately separated nevi and primary melanomas. Multiclass significance analysis of microarrays comparing normal skin, nevi, primary melanomas, and the two types of metastatic melanoma identified 2,602 transcripts that significantly correlated with sample class. These results suggest that melanoma pathogenesis can be understood as a series of distinct molecular events. The gene expression signatures identified here provide the basis for developing new diagnostics and targeting therapies for patients with malignant melanoma.


Related Papers